Cablivi gets positive results for rare blood clotting disorder
Sanofi’s Cablivi has been linked with a 74% reduction in aTTP-related death in a Phase III trial published by the New England Journal of Medicine.
Read More
Tag: Nanobody
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
